Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups. Academic Article uri icon

Overview

abstract

  • The FDA approval of immune checkpoint inhibitors for cancers with tumor mutation burden (TMB) of at least 10 mut/Mb is postulated to reduce healthcare disparities by broadly expanding treatment eligibility. In a cohort of 39,400 patients with available genomic and race data, black and Asian patients were less likely to have TMB-high cancers in multiple types of malignancies based on the currently approved cut-off. Decreasing TMB thresholds preferentially increased the eligibility of minority patients for immune checkpoint inhibitors while retaining predictive value of treatment benefit in a cohort of immune checkpoint inhibitor treated patients. This study highlights differing distributions of TMB-high cancers between racial groups and provides guidance in developing more rational eligibility criteria for immune checkpoint inhibitors.

publication date

  • November 1, 2021

Research

keywords

  • Biomarkers, Tumor
  • Immune Checkpoint Inhibitors
  • Immunotherapy
  • Racial Groups

Identity

PubMed Central ID

  • PMC8603286

Scopus Document Identifier

  • 85120427745

Digital Object Identifier (DOI)

  • 10.1136/jitc-2019-000147

PubMed ID

  • 34795008

Additional Document Info

volume

  • 9

issue

  • 11